Abstract: A vibratory endodontic device is described for mechanical preparation of dental radicular canals, i.e., root canals, prior to their obturation. The device includes a housing, a vibratory drive means supported within the housing to minimize the transfer of vibration to the housing, an endodontic file connected to the drive means for vibratory movement and stop means operatively connected to the housing and substantially isolated from the mechanical vibrations created by the vibratory drive means. Additionally, fluid transport means are provided for maintaining a controllable or a continuous flow of irrigation fluid along the endodontic file. Various assemblies for retaining the endodontic files and the stop means at the operative end of the vibrating device are also described.

Abstract: A controlled release tablet for once-daily oral administration of about 500-1200 mg of naproxen or naproxen sodium, said tablet being a homogeneous matrix comprising about 4-9 weight percent of hydroxypropylmethylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent naproxen or naproxen sodium, 0.1 to about 2 weight percent of a pharmacetucailly acceptable lubricating agent, and 0 to about 8 weight percent of other pharmaceutically acceptable excipients.

Abstract: This invention relates to compounds of the formula: ##STR1## wherein A is biphenyl unsubstituted or substituted on one or both rings with one or more halo, lower alkyl, lower alkoxy or trifluoromethyl substituents; Z is ethylene unsubstituted or substituted with a single lower alkyl substituent or propylene unsubstituted or substituted with one or two lower alkyl substituents; and the pharmaceutically acceptable acid addition salts thereof. These compounds have anticonvulsant activity.

Abstract: Novel compounds of the general formula ##STR1## and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, N-optionally substituted alkylamido, except that when R.sup.1 is methyl, R.sup.4 is not methyl; orR.sup.2 and R.sup.3 together form --OCH.sub.2 O--;R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are each independently hydrogen, lower acyl, aminocarbonylmethyl, cyano, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, di-lower alkyl amino; orR.sup.6 and R.sup.7 together form --CH.dbd.CH--CH.dbd.CH--;R.sup.7 and R.sup.8 together form --OCH.sub.2 O--;R.sup.11 and R.sup.12 are each independently hydrogen or lower alkyl; andW is oxygen or sulfur.

Abstract: 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)guanine are useful as antiviral agents.

Abstract: A method and apparatus for determining the presence of particles in a fluorescent dispersion which exceed either a predetermined fluorescence intensity or size are disclosed. The method and apparatus involve the irradiation of the dispersion with excitation light, the examination of the fluorescent light entering an optical fiber from a portion of the excited region small enough to permit only a low probability that more than one particle of interest is present in the volume during a predetermined period of time, and the measurement of the emitted fluorescence entering the fiber, substantially free of excitation light, to the extent that the fluorescence differs in intensity from that of the dispersion in the absence of the particle.

Abstract: Novel 5-(4-vinyl- or 4-ethynylbenzoyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids represented by the formula ##STR1## and the pharmaceutically acceptable, non-toxic alkyl esters and salts thereof, wherein R is vinyl or ethynyl, and Y is hydrogen, a lower alkyl group having from 1 to 6 carbon atoms, chloro or bromo.

Abstract: Composition and method are provided for enzyme immunoassays for high molecular weight proteins, such as ferritin. An enzyme is conjugated to the high molecular weight protein through a specific linking group. Usually, on the average, about 2 to 10 enzyme molecules are bonded to each protein molecule. In an assay, the conjugate competes with an unknown sample for receptor and the resulting enzymatic activity is compared to a standard for a determination of the presence and amount of protein in the unknown.

Abstract: A method and apparatus are described for enhanced detection relative to background radiation, of electromagnetic signals from an emitter of radiation in response to incident radiation. The method and apparatus have particular applicability in the field of particle detection, e.g. fluorescent particle detection.

Abstract: Novel compounds of the general formula: ##STR1## and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently hydrogen, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl; orR.sup.2 and R.sup.3 together form --OCH.sub.2 O--; andR.sup.10 and R.sup.11 are each independently hydrogen or lower alkyl.These compounds combine .beta.-blockade and calcium entry blockade properties in the same compound and therefore are useful in therapy in the treatment of cardiovascular diseases, including hypertension, arrhythmias and variant and exercise induced angina.

Abstract: This invention relates to a method of treatment of ocular hypertension and to a topical ophthalmic pharmaceutical composition useful for management of ocular hypertension.When administered topically to an eye with increased intraocular pressure, .+-.2-[(3,4-methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-.alpha. -hydroxybenzyl]pyrrolidines effectively decrease intraocular pressure, inhibit the deterioration of the eye due to intraocular hypertension or glaucoma and relieve the symptoms of already existing glaucoma or other ophthalmic disease.